Abbott defeats shareholder lawsuit over 2022 infant formula recall

A federal judge on Friday dismissed a lawsuit accusing Abbott Laboratories of ​defrauding shareholders by downplaying and trying to evade its responsibility for a 2022 ‌recall of powdered infant formula, and lying about its commitment to quality and product safety.

Reuters • Jul 24, 2026

Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.

Zacks Investment Research • Jul 24, 2026

ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

Zacks Investment Research • Jul 23, 2026

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Jul 21, 2026

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.

24/7 Wall Street • Jul 21, 2026

Abbott investigates two separate cyber incidents, says no operations affected

Abbott Laboratories is investigating two cyber incidents involving unauthorized access to ​some internal systems at its cancer diagnostics business and ‌its LabCentral portal, the company said on Friday, adding that its operations were not affected.

Reuters • Jul 17, 2026

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories (NYSE:ABT) reported upbeat second-quarter results and raised its full-year adjusted earnings outlook on Thursday.

Benzinga • Jul 17, 2026

ABT Q2 Earnings Call Flags Stronger Second-Half Setup

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.

Zacks Investment Research • Jul 17, 2026

Abbott Laboratories: Pick Up This Dividend King Deal Now

Abbott Laboratories has rallied sharply since my last "Buy" rating in May. Strength in its core Medical Devices business and the recently acquired Exact Sciences should keep driving strong growth for the company. Abbott Laboratories enjoys an A+ S&P credit rating with a stable outlook.

Seeking Alpha • Jul 17, 2026

Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga • Jul 17, 2026